FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that management of the company will host a pre-recorded conference call to discuss the U.S. Food and Drug Administration approval of Letairis™ (ambrisentan) 5 mg and 10 mg tablets on Friday June 15, 2007 at 2:30 p.m. Pacific time / 5:30 p.m. Eastern time. Letairis is an endothelin receptor antagonist (ERA) indicated for the once-daily treatment of pulmonary arterial hypertension (WHO Group 1) in patients with WHO Functional Class II or III symptoms to improve exercise capacity and delay clinical worsening. The conference call will be webcast through the company’s website at www.gilead.com and will feature John C. Martin, PhD, President and Chief Executive Officer; John F. Milligan, PhD, Chief Operating Officer and Chief Financial Officer; and Kevin Young, Executive Vice President of Commercial Operations.
